Organization · Venture Capital
Ridgeback Capital Management
Ridgeback Capital Management is a New York-based private investment firm focused on life science and biopharma companies. Founded in 2006, it combines public securities trading with long-term private investments, emphasizing patient capital for innovative therapies.
Overview
What Ridgeback Capital Management does
What Ridgeback Capital Management is
Ridgeback Capital Management is a New York-based private investment firm focused on life science and biopharma companies. Founded in 2006, it combines public securities trading with long-term private investments, emphasizing patient capital for innovative therapies.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2006
- Approximate age
- About 20 years
- Structured capabilities
- Funder
- Last reviewed
- April 25, 2026
Official channels
Find Ridgeback Capital Management elsewhere
Open the official website or a supported primary organization account.
Capability profile
Ridgeback Capital Management as a funder
Investment thesis
Ridgeback Capital Management focuses on life science and biopharma investments, emphasizing life-saving and life-changing technologies with unmet needs. The firm adopts a long-horizon investment approach, supporting innovators through patient capital across various stages.
Focus narrative
Ridgeback Capital invests in both private and public companies dedicated to developing life-saving and life-changing therapies. The organization emphasizes the importance of patient capital for the growth of new technologies and companies in the healthcare sector, ensuring that innovators have the necessary support to bring their solutions to market.
Value beyond capital
Ridgeback Capital adds value to its portfolio companies by providing patient capital, strategic guidance, and access to a network of industry experts. The firm’s leadership, particularly Dr. Wayne Holman, leverages extensive experience in the life sciences sector to support the growth and success of its investments.
Focus and fit
- Stages
- Friends and Family · Angel · Pre-seed · Seed · Seed+ · Series A · Series A+ · Series B · Series B+ · Series C · Series C+ · Series D · Series E · Series F · Growth Equity · Pre-IPO · Ipo
- Regions
- North America · Global
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 100
Portfolio context
Ridgeback Capital has a diverse portfolio that includes notable companies such as Harpoon Therapeutics, 4D Molecular Therapeutics, Precision BioSciences, Selecta Biosciences, Adaptimmune, Bellicum Pharmaceuticals, Stem Cell Therapeutics, Microbia, Alveolus, and Nested. These companies are at the forefront of developing innovative therapies in the biopharma space.
Common questions
What to know about Ridgeback Capital Management
Upseed classifies Ridgeback Capital Management under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 25, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.